SCHEMBL2835154

SCHEMBL2835154

OC1CNCCc2sccc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PNMT P11086 1/20 0.46
GID4 Q8IVV7 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.40
GRIN2B Q13224 1/20 0.38
KEAP1 Q14145 1/20 0.38
DRD3 P35462 1/20 0.37
HTR2A P28223 6/20 0.36
HTR2C P28335 6/20 0.36
HTR2B P41595 5/20 0.36
MAPK1 P28482 2/20 0.36
CYP3A4 P08684 1/20 0.36
ALOX15 P16050 1/20 0.36
TSHR P16473 1/20 0.36
NFKB1 P19838 1/20 0.36
THPO P40225 1/20 0.36
HSD17B10 Q99714 1/20 0.36
TAAR1 Q96RJ0 3/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3044542 1.00 PNMT (0.46) PNMTGID4L3MBTL1GRIN2BKEAP1
SCHEMBL3044539 1.00 PNMT (0.46) PNMTGID4L3MBTL1GRIN2BKEAP1
SCHEMBL2835224 0.81 MAPK1 (0.51) PNMTGID4GRIN2BKEAP1MAPK1
Hydrochloric Acid SCHEMBL11012392 0.79 MAPK1 (0.50) PNMTGID4GRIN2BKEAP1MAPK1
SCHEMBL5086491 0.78 HTR2C (0.51) PNMTGID4HTR2AHTR2CHTR2B
SCHEMBL1747061 0.74
SCHEMBL18071812 0.72 HTR2C (0.62) PNMTHTR2AHTR2CHTR2BCYP3A4
SCHEMBL16363089 0.71 ADRA2A (0.45) GID4GRIN2BKEAP1DRD3TAAR1
SCHEMBL16363079 0.71 ADRA2A (0.45) GID4GRIN2BKEAP1DRD3TAAR1
SCHEMBL1745435 0.71 ADRA2A (0.45) GID4GRIN2BKEAP1DRD3TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8217031-B2 Heteroaryl derivatives NIPPON SHINYAKU CO., LTD. (JP) 2012-07-10 US disclosed
US-20100048537-A1 HETEROARYL DERIVATIVES NIPPON SHINYAKU CO., LTD. (JP) 2010-02-25 US disclosed
EP-2141168-A1 HETEROARYL DERIVATIVES Nippon Shinyaku Co., Ltd. (JP) 2010-01-06 EP disclosed
EP-1303521-B1 TETRAHYDRO-HETEROCYCLOAZEPINYL PYRIMIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2005-02-02 EP disclosed
EP-1303521-A1 TETRAHYDRO-HETEROCYCLOAZEPINYL PYRIMIDINE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2003-04-23 EP disclosed
US-20020045635-A1 Novel mGluR antagonists and a method for their synthesis HOFFMANN-LA ROCHE, INC. 2002-04-18 US disclosed
US-6369222-B1 NITRO- AND CYANO-1,2,4,5-TETRAHYDRO-HETEROCYCLOAZEPINYL PYRIMIDINE DERIVATIVES; BRAIN, EYE, MUSCULAR, PSYCHOLOGICAL AND NERVOUS SYSTEM DISORDERS HOFFMANN-LA ROCHE INC. 2002-04-09 US disclosed
WO-2002006288-A1 TETRAHYDRO-HETEROCYCLOAZEPINYL PYRIMIDINE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2002-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020045635-A1 Novel mGluR antagonists and a method for their synthesis GRM1, GRM5, GRM2 PNMT 308/4885GID4 1051/4885L3MBTL1 3851/4885
US-20100048537-A1 HETEROARYL DERIVATIVES OPRD1, OPRM1, OPRK1 PNMT 1313/4885GID4 2747/4885L3MBTL1 2724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.